Event in Progress:
Discover the latest content that has just been published on Research Tree
Biogen delivered an all-around beat in the last result. Its MS product revenue was $1.3 billion, representing a decline of 17% in actual currency and 14% in constant currency which was a setback. TECFIDERA generic competition, ongoing interferon declines and some pricing pressure mostly brought on this reduction. Many generic versions of TECFIDERA have continued to be introduced in numerous European nations. The company also kept up with protecting its intellectual property for TYSABRI. SPINRAZA
Companies: BIOGEN (BIIB:NYSE)Biogen Inc. (BIIB:NAS)
Baptista Research
Biogen’s stock has been on a roll as the company delivered another solid set of results, surpassing Wall Street expectations on all counts. There have been many major developments across its pipeline that includes 12 programs in Phase III that have been filed and the management has raised the full-year financial guidance of the company. Along with Eisai, there have been positive results from Clarity AD, a Phase 3 study of the lecanemab. Leacnemab administration displayed a highly statistically n
Biogen has been in the news for a number of controversies, most of which are associated with its Alzheimer’s drug, Aduhelm. The company is looking to shake off the claims that it misled investors on the assumed success of Aduhelm. However, the company did win a priority review from the U.S. FDA for tofersen, its ALS therapy. On the financial front, Biogen executed well in the second quarter and delivered an all-around beat. Along with Eisai, they are granted priority review for lecanemab under t
Companies: Biogen Inc. (0R1B:LON)Biogen Inc. (BIIB:NAS)
Biogen’s failure of its Alzheimer’s drug, Aduhelm has led to a CEO change with the company looking for a successor to CEO Michael Vounatsos. The company’s MS business generated $1.6 billion in revenue, including Ocrevus royalties in the last quarter and has been performing fairly well. However, they have built a $1 billion dollar cost-saving plan and are significantly reducing spending on Aduhelm as part of designed to refocus the company’s flagging biotech business. The management sees the pote
Biogen witnessed a 4% year over year drop in its top-line in the last quarter as Tecifidera revenue continued to erode in the U.S. due to generic entry. In light of several recent challenges, the company announced that it would implement cost-cutting measures expected to save approximately $500 million annually. On the other hand, they recently announced a deal to sell their Samsung Bioepis joint venture stake to Samsung Biologics, with Biogen continuing to be the commercialization partner for t
Biogen has had a particularly rough year so far. After much anticipation, the company’s Alzheimer's disease drug, Aduhelm was launched amidst huge controversies with respect to its regulatory approval. The drug’s revenues were as low as $0.3 million in the recent quarter with wholesalers reducing inventories on account of lack of clarity on reimbursement. The company’s core portfolio of multiple sclerosis drugs is also witnessing a sharp drop of around 18% in the last quarter given the strong co
Biogen has had one of its most eventful years so far in the history of the company. The company has seemingly made a major breakthrough in its neuroscience portfolio after the accelerated approval of Aduhelm, its medication for patients of the Alzheimer's disease, on which the company’s future had been dependent for a very long time. The management believes that their recent accelerated approval could completely transform the treatment of Alzheimer's disease but it has had its fair share of cont
Research Tree provides access to ongoing research coverage, media content and regulatory news on Biogen Inc.. We currently have 0 research reports from 3 professional analysts.
Companies: Warpaint London PLC
Shore Capital
Feature article: Steady as she goes, but could be better: A review of investment company liquidity since 2016 Liquidity is the lifeblood of equity markets. The measurement of liquid asset availability to a market or company is a way of gauging a market’s health. This article builds on our previous work, which analysed the liquidity data for non-financial trading companies, by applying the same analytical techniques to the investment companies (IC) space. We analyse liquidity for ICs as a whol
Companies: NBPE ICGT ARBB RECI CLIG HAT AVO VTA APAX
Hardman & Co
Avon Protection’s capital markets day highlighted its continued focus on medium-term margin expansion (targeting operating margin of 14–16%), concentrating on its core business of respirators and head protection. The unwinding of the armour business, alongside the consolidation of Team Wendy (acquired in H220) should enable Avon to benefit from rising global defence spending. Its strong relationship with the US DoD, and organic growth opportunities with recurring revenue from necessary product r
Companies: Avon Protection PLC
Edison
Companies: SCE HVO VLG
Cavendish
15th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: Change of Market: TheWorks (WRKS.L) a multi-channel value retailers of books, arts and crafts, stationery, toys and games, offering customers a differentiated propositio
Companies: GTC SAV FAB KRM BOOM
Hybridan
Companies: IGP RUA BOOM
17th April 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced Dish of the day Admissions: Delistings: What’s baking in the oven? ** Potential**** Initial Public Offerings: Reverse Takeovers: 16 April 2024: Electric Guitar (ELEG.L) Concurrent with its Admission to trading on AIM, Electric Guitar is proposing to acquire the entire issued share capital of 3radi
Companies: ARS TIDE SCE SNX ECK CNS TST SPEC SSTY
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of products used in biosurgery, orthopaedics and dental markets. Investment in tissue processing, manufacturing capacity and strong commercial partners, together with its “4S” strategy, has generated six consecutive reporting periods of strong growth, with TRX turning EBITDA-positive in 2023. Further growth in 202
Companies: Tissue Regenix Group plc
Cambridge Nutritional Sciences (CNS) has published its H1 2024 results to end September 2023. Group revenues grew 44% to £4.9m and gross profits increased by 63% to £3.1m, with the company benefitting from newfound operational efficiencies. With its now streamlined strategy focussing on the core Health & Nutrition business and the initial signs of an encouraging uptick in sales momentum, we believe the company is well positioned for growth that will help create future value for shareholders. We
Companies: Cambridge Nutritional Sciences PLC
Companies: BILN IGP RBN SBTX
Venture Life has reported FY23 results to December 2023, following the February trading update. Revenues grew 17% in the year to £51.4m (our est. £50.7m) and adjusted EBITDA was £11.6m (our est. £11.6m). Cash conversion was 85%, generating £9.8m of cash from operations. Cash generation and no M&A in 2023 allowed the company to de-lever, closing FY23 with net debt to adjusted EBITDA at 1.3x. Management have focused on growth with three therapy areas generating double-digit revenue growth and onli
Companies: Venture Life Group Plc
Creo Medical has released a trading update for FY23, an active year for the company, with progress made across all business segments. Traction improved in H223, following Speedboat Inject’s European clearance for upper gastrointestinal (GI) procedures and the accelerated approval and launch of Creo’s slimmest electrosurgical device, Speedboat UltraSlim. Top-line growth was supported by continued streamlining of the cost structure, resulting in a better-than-expected underlying EBITDA loss (impro
Companies: Creo Medical Group Plc
Zoetis delivered a decent set of results for the last quarter of 2022 meeting analyst expectations as well as the high end of its management guidance. Despite the economic challenges, ongoing pandemic recovery, and the political unpredictability brought on by the war in Ukraine, they delivered operational growth for the year in each of their top 13 markets. The company's unique companion animal portfolio drove its 8% operational revenue increase for the year, growing 14% operationally. In compar
Companies: Zoetis (ZTS:NYSE)Zoetis, Inc. Class A (ZTS:NYS)
Share: